AbbVie: Margin Clarity, Dividend Durability Awaited

Core Insights - AbbVie is experiencing stability in price action and offers attractive dividend yields, but there are underlying issues in the investment thesis beyond the aging Humira patent cliff [1] Group 1: Company Analysis - AbbVie is facing challenges related to the expiration of the Humira patent, which is a significant concern for its future revenue streams [1] - The company has a strong focus on equity valuation, market trends, and portfolio optimization to identify high-growth investment opportunities [1] Group 2: Analyst Background - The analysis is conducted by a seasoned analyst with over 20 years of experience in quantitative research, financial modeling, and risk management, emphasizing a long-term perspective on value creation [1] - The analyst has previously held a Vice President position at Barclays, leading teams in model validation and stress testing, showcasing a deep expertise in both fundamental and technical analysis [1]